Company: PSTV
Filing Date: 2025-06-20
Form Type: S-1/A
Source: 0001193125-25-142935
Chunk: 4

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-20
Form: S-1/A
Chunk 4
---
 INFORMATION                                                 |     | 26 |
| INCORPORATION BY REFERENCE                                                          |     | 27 |
| DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES |     | 28 |

i

ABOUT THIS PROSPECTUS

This prospectus forms part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), and
that includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings
“Where You Can Find More Information” and “Incorporation by Reference” before making your investment decision.

You
should rely only on the information provided in this prospectus or in a prospectus supplement or any free writing prospectuses or amendments thereto. Neither we, nor the selling stockholder, have authorized anyone else to provide you with different
information. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus is accurate only as of the date hereof. Our business, financial condition, results
of operations and prospects may have changed since that date.

Neither we, nor the selling stockholder, are offering to sell or seeking
offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that
purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to
distribution of the prospectus outside of the United States.

Unless the context otherwise requires, references in this prospectus to
“Plus,” “the Company,” “we,” “us” and “our” refer to Plus Therapeutics, Inc. Our logo and all product names are our common law trademarks. Solely for convenience, trademarks and tradenames referred
to in this prospectus may appear without the or symbols, but such references are not intended to indicate in any way that we will
not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.

ii

PROSPECTUS SUMMARY

This summary contains basic information about us and this offering. Because it is